NCT06691360View on ClinicalTrials.gov

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

87

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

August 31, 2027

Conditions

Advanced Malignant Tumors

Interventions

DRUG

AK137

IV infusion, specified dose on specified days.

Trial Locations (1)

Unknown

Shanghai Pulmonary Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY